These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9612845)

  • 21. Pharmacokinetic parameters of bromperidol in Korean subjects.
    Lee SY; Kim YG; Kim HG; Kim JW
    Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
    Fujii Y; Tateyama M; Kamisada M; Tanoue A; Takamiya M; Nakajima S; Itoh H
    Folia Psychiatr Neurol Jpn; 1984; 38(2):121-36. PubMed ID: 6152433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Otani K; Furukori H; Kaneko S; Inoue Y
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(2):57-9. PubMed ID: 11407439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
    Suzuki H; Gen K; Inoue Y
    J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depot bromperidol decanoate for schizophrenia.
    Wong D; Adams CE; David A; Quraishi SN
    Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromperidol decanoate (depot) for schizophrenia.
    Purgato M; Adams CE
    Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
    Benfield P; Ward A; Clark BG; Jue SG
    Drugs; 1988 Jun; 35(6):670-84. PubMed ID: 3048975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
    Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y
    Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromperidol radioimmunoassay: human plasma levels.
    Tischio J; Hetyei N; Patrick J
    J Pharm Sci; 1984 Apr; 73(4):546-8. PubMed ID: 6726642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.